Antifungal agent-169

Antifungal agent-169 (compound 5p) potently inhibits fluconazole-sensitive Candida albicans SC5314 with an MIC₅₀ of 0.28 μM; it also exhibits synergistic activity against Candida albicans SC5314-FR when combined with Fluconazole (HY-B0101) (FICI = 0.26)^[1].
Antifungal agent-169 (0.14-0.56 μM; 96 h) exerts a sustained time-dependent inhibitory effect on the proliferation of Candida albicans SC5314^[1].
Antifungal agent-169 (0.14-0.56 μM) inhibits Candida albicans biofilm formation in a concentration-dependent manner at concentrations of 0.14, 0.28, and 0.56 μM^[1].
Antifungal agent-169 (0.14-0.56 μM; 4 h, 8 h) potently inhibits hyphal growth of *Candida albicans* SC5314 in Spider medium and SD + 10% FBS medium at concentrations of 0.14, 0.28 and 0.56 μM after 4 h and 8 h of treatment, and its efficacy is superior to that of fluconazole^[1].
Antifungal agent-169 (0.15-5 μM; 24 h) shows no significant cytotoxicity against human bronchial epithelial 16HBE cells after treatment at concentrations up to 5 μM for 24 h, and maintains a cell viability of over 90%^[1].
Antifungal agent-169 (0.14-0.56 μM) significantly downregulates the expression of cAMP-PKA pathway genes *RAS1*, *EFG1*, *BCR1*, *ECE1* and *HWP1* in *Candida albicans* SC5314^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.